We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZD:NASDAQZiff Davis, Inc. Analysis

Data as of 2026-05-12 - not real-time

$41.90

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ziff Davis trades at $41.90, just above the calculated support of $40.36 and below its 20‑day SMA of $45.89, indicating short‑term pressure while still sitting above the 200‑day SMA of $37.18. The RSI of 38.9 points to a mildly oversold condition, but the MACD histogram remains negative and the MACD line sits beneath the signal, signaling bearish momentum in the near term. Valuation metrics show a trailing P/E of 35.8 versus an industry average of 17, yet a forward P/E of 7.9 and a DCF‑derived fair value of $95.54 suggest the stock may be priced undervalued by roughly 10 % according to the model. Volume is on an upward trend, and the beta of 0.89 points to lower systematic risk than the broader market, though 30‑day volatility is high at 32.8 %.
The company reported an 1.9 % YoY revenue decline and modest profit margins, but management is pivoting toward asset monetization, selective acquisitions and share repurchases, as highlighted in recent earnings commentary. Analysts remain optimistic, assigning a “Buy” consensus with median price targets around $48 and a forward EPS outlook of $5.31, implying strong earnings growth potential. The balance sheet shows $517 M in cash against $894 M of debt, yielding a debt‑to‑equity of ~52 % and a low ROE of 2 %, underscoring both leverage concerns and the need for cash‑flow conversion. Overall, the stock’s upside potential, improving earnings guidance and strategic realignment outweigh the near‑term technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support
  • Bearish MACD and modest upside
  • Recent revenue miss

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E of 7.9 indicating earnings growth
  • Asset‑monetization strategy and buyback program
  • Analyst consensus buy with median target $48

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value suggests ~10% upside
  • High gross margin and diversified digital portfolio
  • Lower beta and strong cash position despite debt

Key Metrics & Analysis

Financial Health

Revenue Growth-1.90%
Profit Margin3.14%
P/E Ratio35.8
ROE2.08%
ROA3.40%
Debt/Equity51.95
P/B Ratio0.9
Op. Cash Flow$416.4M
Free Cash Flow$-20506376
Industry P/E17.0

Technical Analysis

TrendBullish
RSI39.0
Support$40.36
Resistance$48.96
MA 20$45.89
MA 50$43.48
MA 200$37.18
MACDBearish
VolumeIncreasing
Fear & Greed Index87.96

Valuation

Fair Value$95.54
Target Price$46.43
Upside/Downside10.82%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.89
Volatility32.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.